Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03615157
Other study ID # CEP 411/14
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 15, 2018
Est. completion date February 15, 2019

Study information

Verified date July 2018
Source University of Sao Paulo
Contact Naomi K Nakagawa, PhD
Phone +551130618529
Email naomi.kondo@fm.usp.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heart failure (HF) is a multisystemic disease leading to exercise intolerance and fatigue. Supervised physical training improves functional capacity, quality of life and reduces hospital admissions in HF patients. In this way, home physical training may be a good alternative to patients who, for any reason, cannot perform supervised training. Objective: To asses the effects of a home-based training program on functional capacity, sedentary lifestyle and quality of life of patients with chronic HF compared to supervised training.


Description:

After agreement with the written informed consent, subjects with heart failure (left ventricle ejection fraction bellow or equal 40%) will be included in this study. They will be randomized in two groups: Home-based and Supervised exercise groups. The two groups will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. All volunteers will be assessed at baseline and after twelve weeks of intervention. Peripheric and respiratory muscle strength as well the 6MW analyses were assessed also at 4 and 8 weeks after baseline.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date February 15, 2019
Est. primary completion date December 15, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Chronic heart failure (functional class from NYHA II and III),

- Left ventricle ejection fraction bellow or equal to 40%

- Clinical stability during the last three months

- Medical release for physical training after cardiopulmonary test

Exclusion Criteria:

- Uncontrolled arrhythmia

- Pulmonary artery systolic pressure > 35 mmHg by the echo doppler cardiogram,

- Peripheral oxygen saturation < 92% in resting condition

- Respiratory infection in the previous 30 days to the enrollment into the study

- Cognitive, neurological or orthopedic limitations

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise rehabilitation
Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.

Locations

Country Name City State
Brazil Instituto Dante Pazzanese de Cardiologia Sao Paulo
Brazil School of Medicine, University of Sao Paulo São Paulo SP

Sponsors (4)

Lead Sponsor Collaborator
University of Sao Paulo Fundação de Amparo à Pesquisa do Estado de São Paulo, InCor Heart Institute, Instituto Dante Pazzanese de Cardiologia

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in peak oxygen uptake (ml/kg/min) Patients will be submitted to cardiopulmonary treadmill exercise tests at baseline and after 12 weeks. Baseline and after 12 weeks of exercise programs
Secondary Incidence of cardiac events and arrhythmia By a 24-hours holter system for continuous recording of ambulatory electrocardiographic signs Baseline and after 12 weeks of exercise programs
Secondary Changes in distance from the six minute walk test (6MW, m) Patients will be submitted to the 6MW accordingly to the American Thoracic guidelines to assess functional capacity using the six minute walk test Baseline and after 4, 8 and 12 weeks of exercise programs
Secondary Changes in respiratory muscle strength (cmH2O) Inspiratory and expiratory muscle strength will be assessed using an analogic pressure transducer Baseline and after 4, 8 and 12 weeks of exercise programs
Secondary Changes in peripheral muscle strength (N) - Quadriceps mm Quadriceps strength will be assessed by MicroFet 2 dynamometer (HogganHealth, USA) Baseline and after 4, 8 and 12 weeks of exercise program
Secondary Changes in peripheral muscle strength (kgf) - Hand grip Hand grip strength will be assessed by Jamar dynamometer (Sammons Preston Rolyan, 4, Sammons Court, Bolingbrook, IL, 60440) Baseline and after 4, 8 and 12 weeks of exercise programs
Secondary Changes in daily physical activity and sedentary lifestyle Patients will use the accelerometer GT3X (Actigraph, Pensacola, FL, USA) on waist during 9 days to asses daily physical activity and sedentary lifestyle Baseline and after 12 weeks of exercise programs
Secondary Changes in International Physical Activity Questionnaire (IPAQ) Patients will be classified as sedentary, irregularly active, active or very active according to Matsudo`s Classification (2001) Baseline and after 12 weeks of exercise programs
Secondary Changes in quality of life using SF-36 Quality of life will be assessed by the Short Form-36 Questionnaire Baseline and after 12 weeks of exercise programs
Secondary Changes in quality of life using MLHF Quality of life will be assessed by the Minnesota Living with Heart Failure Questionnaire Baseline and after 12 weeks of exercise programs
Secondary Changes in brain natriuretic peptide (BNP, pg/mL) A blood sample of 5 ml will be collected in a tube and BNP will be measured Baseline and after 12 weeks of exercise programs
Secondary Changes in heart rate variability (HRV) HRV will be analysed from the spectral analysis of R-R intervals obtained from a heart rate monitor (Polar, S810, Kempele, Finland) during the 6MW Baseline and after 12 weeks of exercise programs
Secondary Changes in sleep quality Patients will use the accelerometer GT3X (Actigraph, Pensacola, FL, USA) on wrist for nine days to asses Sleep quality. Furthermore, the Pittsburgh Sleep Quality Index will be used to classify patients as good or poor sleepers. Baseline and after 12 weeks of exercise programs
Secondary Changes in daytime sleepiness Daytime sleepiness will be assessed by the Epworth Sleepiness Scale Baseline and after 12 weeks of exercise programs
See also
  Status Clinical Trial Phase
Completed NCT03597646 - The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure N/A
Terminated NCT04065997 - Apogee International
Withdrawn NCT03675113 - Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure N/A
Completed NCT02916160 - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study Phase 4
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Completed NCT02268500 - VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT) Phase 4
Completed NCT02247245 - The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients. N/A
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT01919918 - Muscle Afferent Feedback Effects in Patients With Heart Failure Phase 1
Not yet recruiting NCT01669395 - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial N/A
Completed NCT00984529 - Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia N/A
Recruiting NCT00863421 - Sleep Disordered Breathing in Patients With Chronic Heart Failure N/A
Completed NCT02840565 - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 Phase 1
Completed NCT02441218 - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study Phase 3
Completed NCT00149409 - Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure Phase 2/Phase 3
Terminated NCT05532046 - A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT) Phase 1
Recruiting NCT04984928 - Readmission Risk of Patients With Heart Failure.
Completed NCT02814097 - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction Phase 2
Active, not recruiting NCT05560737 - ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
Recruiting NCT03286127 - Palliative Outcome Evaluation Muenster I